
Opinion|Videos|July 18, 2024
Future of TROP2- and HER2-Directed ADCs in Breast Cancer
Author(s)Aditya Bardia, MD, MPH, Laura Huppert, MD
Laura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, provide closing thoughts on the evolving treatment landscape for HER-negative and HER2-low metastatic breast cancer.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- What do you envision for the role of ADCs in the future treatment of HER-negative and HER2-low metastatic breast cancer?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
Managing Toxicity and Safety of Belzutifan in ccRCC
3
Spotlighting Sequencing and Biomarkers in Bladder Cancer Management
4
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
5




















